Denys-Drash Syndrome and Risk of Post-transplant Lymphoproliferative Disorder

计划入组 108 人 · 首次发布于 2026 年 5 月 26 日

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

首次发布于 2017 年 3 月 22 日

Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

计划入组 6 人 · 首次发布于 2020 年 4 月 8 日

Tabelecleucel(Ebvallo)

Fungi based microdose therapeutic (post-traumatic stress disorder)

TBM-TRANSPLANT (Heart)

Transplant Genomics Inc.

United States

WOMB TRANSPLANT UK

United Kingdom

MUSCULOSKELETAL TRANSPLANT FOUNDATION

United States

Viracta Therapeutics' Nana-Val Shows Promise in Post-Transplant Lymphoproliferative Disorder

Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients

Three Essential Medicines Classified as Carcinogenic by IARC; Experts Urge Continued Treatment with Monitoring